Transportation costs impede sustained adherence and access to HAART in a clinic population in Southwestern Uganda: A qualitative study

AIDS and Behavior

Volumn 14, Issue 4, 2010, Pages 778-784

  Tuller, David M ^a   Bangsberg, David R ^b   Senkungu, Jude ^c   Ware, Norma C ^b   Emenyonu, Nneka ^b   Weiser, Sheri D ^d,e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Access; Adherence; ARVs; HIV AIDS; Transportation; Uganda

Indexed keywords

ADULT; AMBULATORY CARE; ARTICLE; COST; ECONOMICS; FEMALE; HEALTH CARE DELIVERY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; RURAL POPULATION; SOCIOECONOMICS; TRAFFIC AND TRANSPORT; UGANDA;

ADULT; AMBULATORY CARE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COSTS AND COST ANALYSIS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITATIVE RESEARCH; RURAL POPULATION; SOCIOECONOMIC FACTORS; TRANSPORTATION; UGANDA;

EID: 77956876156     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-009-9533-2     Document Type: Article

References (27)

1. Bangsberg D. R., Hecht F. M., Charlebois E. D., Zolopa A. R., Holodniy M., Sheiner L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS (London, England) 14 (4) 357-366. doi:10.1097/00002030-200003100-00008. (Pubitemid 30182431)
2. Bangsberg, D. R., Perry, S., Charlebois, E. D., Clark, R. A., Roberston, M., Zolopa, A. R., et al. (2001). Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (London, England), 15(9), 1181-1183. doi:10.1097/0000 2030-200106150-00015.
3. Bangsberg, D. R., Ware, N., & Simoni, J. M. (2006). Adherence without access to antiretroviral therapy in sub-Saharan Africa? AIDS (London, England), 20(1), 140-141. doi:10.1097/01.aids. 0000196168.50303.31.
4. Behforouz, H. L., Farmer, P. E., & Mukherjee, J. S. (2004). From directly observed therapy to accompagnateurs: Enhancing AIDS treatment outcomes in Haiti and in Boston. Clinical Infectious Diseases, 38(Supp 5), S429-S436. doi:10.1086/421408. (Pubitemid 38738542)
5. Byakika-Tusiime, J., Oyugi, J. H., Tumwikirize, W. A., Katabira, E. T., Mugyenyi, P. N., & Bangsberg, D. R. (2005). Adherence to HIV antiretroviral therapy in HIV? Ugandan patients purchasing therapy. International Journal of STD and AIDS, 16(1), 38-41. doi:10.1258/0956462052932548. (Pubitemid 40193660)
6. Carlucci, J. G., Kamanga, A., Sheneberger, R., Shepherd, B. E., Jenkins, C. A., Spurrier, J., et al. (2008). Predictors of adherence to antiretroviral therapy in rural Zambia. Journal of Acquired Immune Deficiency Syndromes, 47(5), 615-622. doi:10.1097/ QAI.0b013e318165dc25.
7. Crane, J. T., Kawuma, A., Oyugi, J. H., Byakika, J. T., Moss, A., Bourgois, P., et al. (2006). The price of adherence: Qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS and Behavior, 10(4), 437-442. doi:10.1007/ s10461-006-9080-z.
8. Creswell, J. (1998). Qualitative inquiry and research design: Choosing among five traditions. Thousand Oaks, CA: Sage Publications, Inc.
9. Farmer, P. (1999). Pathologies of power: Rethinking health and human rights. American Journal of Public Health, 89(10), 1486-1496. doi:10.2105/AJPH.89.10.1486.
10. Gill, C.J., Hamer, D.H., Simon, J.L., Thea, D. M., & Sabin, L.L.(2005). No room for complacency about adherencetoantiretroviral therapy in sub-Saharan Africa. AIDS (London, England), 19(12), 1243-1249. doi:10.1097/01.aids.0000180094.04652.3b.
11. Hardon, A. P., Akurut, D., Comoro, C., Ekezie, C., Irunde, H. F., Gerrits, T., et al. (2007). Hunger, waiting time and transport costs: Time to confront challenges to ART adherence in Africa. AIDS Care, 19(5), 658-665. doi:10.1080/09540120701244943. (Pubitemid 46763738)
12. Ivers, L. C., Kendrick, D., & Doucette, K. (2005). Efficacy of antiretroviral therapy programs in resource-poor settings: A meta-analysis of the published literature. Clinical Infectious Diseases, 41(2), 217-224. doi:10.1086/431199. (Pubitemid 40962502)
13. Koenig, S. P., Leandre, F., & Farmer, P. E. (2004). Scaling-up HIV treatment programmes in resource-limited settings: The rural Haiti experience. AIDS (London, England), 18(Suppl. 3), S21-S25. doi: 10.1097/00002030-200406003- 00005. (Pubitemid 39037455)
14. Kumarasamy, N., Safren, S. A., Raminani, S. R., Pickard, R., James, R., Krishnan, A. K., et al. (2005). Barriers and facilitators to antiretroviral medication adherence among patients with HIV in Chennai, India: A qualitative study. AIDS Patient Care and STDs, 19(8), 526-537. doi:10.1089/apc.2005.19.526. (Pubitemid 41262633)
15. Laurent, C., Diakhate, N., Gueye, N. F., Toure, M. A., Sow, P. S., Faye, M. A., et al. (2002). The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS (London, England), 16(10), 1363-1370. doi: 10.1097/00002030-200207050-00008. (Pubitemid 34722068)
16. Mills, E. J., Nachega, J. B., Bangsberg, D. R., Singh, S., Rachlis, B., Wu, P., et al. (2006). Adherence to HAART: A systematic review of developed and developing nation patient-reported barriers and facilitators. PLoS Medicine, 3(11), e438. doi: 10.1371/journal.pmed.0030438. (Pubitemid 44875939)
17. Mshana, G. H., Wamoyi, J., Busza, J., Zaba, B., Changalucha, J., Kaluvya, S., et al. (2006). Barriers to accessing antiretroviral therapy in Kisesa, Tanzania: A qualitative study of early rural referrals to the national program. AIDS Patient Care and STDs, 20(9), 649-657. doi:10.1089/apc.2006.20.649.
18. Mukherjee, J. S., Ivers, L., Leandre, F., Farmer, P., & Behforouz, H. (2006). Antiretroviral therapy in resource-poor settings. Decreasing barriers to access and promoting adherence. Journal of Acquired Immune Deficiency Syndromes, 43(Suppl. 1), S123-S126. doi:10.1097/01.qai.0000248348.25630.74. (Pubitemid 44885651)
19. Orrell, C., Bangsberg, D. R., Badri, M., & Wood, R. (2003). Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (London, England), 17(9), 1369-1375. doi: 10.1097/00002030-200306130-00011. (Pubitemid 36819851)
20. Oyugi, J. H., Byakika-Tusiime, J., Charlebois, E. D., Kityo, C., Mugerwa, R., Mugyenyi, P., et al. (2004). Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes, 36(5), 1100-1102. doi:10.1097/00126334-200408150-00014. (Pubitemid 38989377)
21. Rosen, S., Fox, M. P., & Gill, C. J. (2007). Patient retention in antiretroviral therapy programs in sub-Saharan Africa: A systematic review. PLoS Medicine, 4(10), e298. doi:10.1371/ journal.pmed.0040298. (Pubitemid 350035458)
22. Safren, S. A., Kumarasamy, N., James, R., Raminani, S., Solomon, S., & Mayer, K. H. (2005). ART adherence, demographic variables and CD4 outcome among HIV-positive patients on antiretroviral therapy in Chennai, India. AIDS Care, 17(7), 853-862. doi: 10.1007/b138963.
23. Uganda Country Profile. (2008). United Kingdom Department for International Development. http://www.dfid.gov.uk/countries/ africa/uganda.asp. Accessed 3 Oct 2008.
24. Ware, N. C., Wyatt, M. A., & Bangsberg, D. R. (2006). Examining theoretic models of adherence for validity in resource-limited settings. A heuristic approach. Journal of Acquired Immune Deficiency Syndromes, 43(Suppl. 1), S18-S22. doi:10.1097/ 01.qai.0000248343.13062.4b.
25. Weidle, P. J., Wamai, N., Solberg, P., Liechty, C., Sendagala, S., Were, W., et al. (2006). Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet, 368(9547), 1587-1594. doi:10.1016/S0140- 6736(06)69118-6. (Pubitemid 44767594)
26. Weiser, S., Wolfe, W., Bangsberg, D., Thior, I., Gilbert, P., Makhema, J., et al. (2003). Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. Journal of Acquired Immune Deficiency Syndromes, 34(3), 281-288. doi: 10.1097/00126334-200311010-00004. (Pubitemid 37377361)
27. Wood, E., Hogg, R. S., Yip, B., Quercia, R., Harrigan, P. R., O'Shaughnessy, M. V., et al. (2003). Higher baseline levels of plasma human immunodeficiency virus type1RNA are associated with increased mortality after initiation of triple-drug antiretro-viral therapy. The Journal of Infectious Diseases, 188(10), 1421-1425. doi:10.1086/379201. (Pubitemid 37523926)